SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

The upcoming SpaceX IPO is driving intense market speculation, with investors debating whether the company represents a transformative 'supercycle' opportunity or an overhyped asset. Community discourse is heavily focused on the company's valuation, its potential integration with AI infrastructure, and the downstream impact on existing space sector stocks and ETFs.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is attracting significant community attention due to its role in high-profile institutional pilots, including tokenized deposit projects involving major global banks. Investors are closely monitoring its limited token supply and interoperability technology as potential long-term catalysts, even as the community debates current price consolidation and future adoption timelines.

What is Chromia? Chromia is an open source public blockchain conceived of by Swedish company Chromaway AB. The Chroma token (CHR) was launched in May of 2019. The technology behind the Chromia blockchain is adapted from an earlier technology called ‘Postchain’, a solution provided by Chromaway AB for enterprise clients.&nbsp;  How does Chromia work? Chromia is a standalone Layer-1 blockchain and EVM compatible Layer-2 enhancement for Binance Smart Chain and Ethereum. It is designed to enhance existing dApps and allow for the creation of next-generation dApps by providing scalability, improved data handling, and customizable fee structures. The blockchain uses a unique architecture called relational blockchain, as well as a custom programming language called Rell.  Rell is designed to code and function very similarly to SQL, allowing developers to leverage the security and immutability of blockchain while storing and handling data with the efficiency of a relational database.&nbsp; Each dApp running on Chromia operates on its own sidechain which is rooted in the main blockchain. This allows each application to scale more efficiently and gives each application developer the freedom to choose from a variety of fee structures. For example, one application may require users to pay transaction fees in CHR (similar to how Ethereum or Bitcoin work), while another application could stake enough CHR to reserve computational power and allow their users to make unlimited transactions without paying any fees at all.&nbsp;  What applications have been built on Chromia? Chromia already has a wide variety of applications building upon their blockchain, using their chain as a decentralized storage layer, and using their Layer-2 enhancements. These applications range from DeFi options trading platform Hedget, to open world farming game My Neighbor Alice, to government land registry initiative LAC PropertyChain.&nbsp; One of the latest features in development is a new NFT standard called Chromia Originals, which will operate both as a native standard on Chromia’s chain as well as an enhancement layer for existing ERC-721 and BEP-721 tokens. Work on these Layer-2 enhancements are being developed in cooperation with My Neighbor Alice.  Who is behind Chromia? Chromia’s core team consists of industry veterans Or Perelman, Henrik Hjelte and Alex Mizrahi. All three have deep roots in the crypto space, going back to the early days of Bitcoin and Ethereum. For example, Alex published several early academic papers on Proof of Stake consensus and was also one of the key figures behind Colored Coins, one of the first projects to develop the idea of ‘tokens’ that would later be brought to prominence by Ethereum.  In summary, Chromia is a Layer-1 and Layer-2 blockchain solution under active development, with the goal of delivering enhanced features and data handling and storage capabilities to decentralized applications.

Chromia

Chromia is trending as investors focus on its potential as a gaming and metaverse play, with community members actively discussing its L1 technology and long-term utility. The conversation is driven by excitement surrounding mainnet developments and comparisons to other successful metaverse projects.

MATH is a one stop crypto solution platform which contains MathWallet, MATH VPOS Pool, MathDEX, MATH dApp Store, MATH Staking, MATH Pay, MATH Chain, etc.

MATH

MATH is trending as community members speculate on the potential for a massive price breakout, driven by its low market capitalization and the hope for a return to historical highs. While some investors are accumulating in anticipation of a seasonal rally, others remain highly skeptical, frequently debating the project's utility and the CEO's management.

Ethereum Classic

Ethereum Classic is trending as investors debate whether the asset is facing a definitive decline or setting up for a potential recovery following a prolonged period of stagnant price action. Community sentiment remains deeply polarized, with active discussions focused on historical technical patterns, the impact of broader market catalysts, and persistent comparisons to other legacy altcoins.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is trending as the community highlights the platform's utility, such as its lending protocol and integration with various Solana assets, while users actively discuss its role in the broader ecosystem. Conversation is further fueled by excitement around the strict list, its function as a primary DEX for trading meme tokens, and persistent community advocacy for its long-term potential.

ProShares Trust - PowerShares UltraShort Lehman 20+ Year Treasury ProShares 2x Shares

ProShares UltraShort 20+ Year Treasury ETF

TBT is trending as investors aggressively hedge against surging Treasury yields, which are being driven by persistent inflation concerns, concerns over mounting government debt, and a shift in sentiment regarding Federal Reserve policy. The community is actively debating the sustainability of the current bond sell-off, with many traders leaning into inverse bond vehicles as they bet on higher rates remaining the status quo.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the Design Automation and Design IP segments. The Design Automation segment includes silicon design, verification of products and services, and Ansys products, and system integration of products and services. The Design IP segment refers to interface, foundation, security, and embedded processor IP, IP subsystems, and IP implementation services that serve companies primarily in the semiconductor and electronics industries. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys Inc

Synopsys is trending as investors react to a significant $2 billion strategic investment from Nvidia, which aims to accelerate AI-driven engineering and chip design through a multi-year partnership. The community is actively discussing how this collaboration, along with the recent acquisition of Ansys, strengthens the company's position as a critical infrastructure provider in the semiconductor industry despite ongoing market volatility and macro headwinds.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

The S&P 500 Equal Weight ETF is currently the focal point of a debate over market breadth, as investors question whether recent record highs are sustainable given the divergence between narrow mega-cap leadership and lagging broader components. Community sentiment is deeply split, with many analysts tracking the performance of the equal-weight index as a critical barometer for whether a healthy rotation into smaller or value-oriented names is actually occurring, or if the market is dangerously reliant on a select group of concentrated technology winners.

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Journey Medical Corp

Journey Medical is currently the subject of intense investor attention ahead of its quarterly earnings, driven by strong growth indicators for its key product, Emrosi, and growing optimism regarding insurance coverage and payer access. The community is actively discussing the stock's significant short interest and the potential for a short squeeze, while emphasizing that recent fundamentals and prescription demand metrics support a bullish long-term thesis for the specialty dermatology firm.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Achieve Life Sciences Reports Q1 2026 Results: Full Earnings Call Transcript

Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Tuesday

Achieve Life Sciences (NASDAQ:ACHV) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-achieve-life-sciences-inc-stock...

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above 200 Day Moving Average   - Time to Sell?

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of "Buy" by Brokerages

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) has been assigned an average recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports...

<ul class="summary-bullets"><li>Achieve on Monday appointed physician Andrew D. Goldberg as CEO and a member of its Board of Directors.</li><li>Separately, the company also said that it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for gross proceeds up to approximately $354 million.&nbsp;</li><li>Achieve is now looking forward to launching cytisinicline for nicotine dependence in the first half of 2027.</li></ul><p><br>Shares of Achieve Life Sciences Inc. (ACHV) gained 42% on Thursday after the company appointed a new CEO, shortly after announcing a private placement of up to $354 million, as it gears towards getting regulatory approval for its experimental drug for the treatment of nicotine dependence.</p><p>The stock is on track to clock its best day since February 2019, if gains hold.</p><h2 class="st-heading-2">New CEO, Board Appointments</h2><p>Achieve on Monday appointed physician Andrew D. Goldberg as CEO and a member of its Board of Directors. Goldberg, who most recently served as a Portfolio Manager at Marshall Wace, will replace Richard Stewart as CEO.</p><p>The company also appointed Lucian Iancovici and Aaron E. Royston as members of the company’s board of directors.</p><h2 class="st-heading-2">Fresh Funding</h2><p>Separately, the company also said that it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities.</p><p>The placement includes an initial upfront funding of approximately $180 million and an additional amount of up to approximately $174 million on exercise of milestone-driven warrants. The net proceeds from the placement is expected to fund a clinical trial for cytisinicline for e-cigarette cessation, the commercialization of cytisinicline, and for working capital and general corporate purposes, the company said.</p><h2 class="st-heading-2">Near-Term Milestones</h2><p>Achieve is now looking forward to the U.S. Food and Drug Administration’s approval of cytisinicline as a treatment for nicotine dependence.</p><p>Earlier this week, the company said that it expects the FDA to reject its current application by June 20, provided that the agency found manufacturing concerns at its third-party manufacturing facility. Once the formal rejection is received, the company expects to resubmit its application naming &nbsp;Adare Pharma Solutions as its manufacturer for commercial supply in the fourth quarter of 2026, it said. The company continues to expect to launch cytisinicline in the first half of 2027.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around ACHV stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.</p><p>A Stocktwits user expressed optimism for the company getting acquired after approval for cytisinicline.</p><p><stembedurl>https://www.stocktwits.com/Biotech_Pharma_Investor/message/650482761</stembedurl></p><p>Another user expressed optimism for a good year following the “professional” announcements.</p><p><stembedurl>https://www.stocktwits.com/Sieppo/message/650471510</stembedurl></p><p><a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> has more than doubled over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/hubc-stock-tanks-after-massive-rally-reverse-split/cZJvo99RIDA">HUBC Stock Declines 35% After A Whopping Two-Day Rally – What’s Driving The Change In Momentum?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Achieve Life Sciences logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?

Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter. 

Equity

Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter. 


Achieve Life Sciences' (ACHV) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the firm...

What is Zacks Research's Estimate for ACHV FY2026 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Zacks Research dropped their FY2026 earnings per share estimates for shares of Achieve Life Sciences in a note issued to investors on...

HC Wainwright Has Positive Estimate for ACHV FY2026 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 earnings estimates for shares of Achieve Life Sciences in a research report issued...

Achieve Life Sciences Flags FDA Observations While Pushing Launch To 2027 For Smoking Cessation Med

Achieve Life Sciences taps Adare for cytisinicline manufacturing as stock falls; reports wider losses and shifts US launch timeline to 2027.read more...

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

ACHV
Achieve Life Sciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest ACHV News

ACHVAchieve Life Sciences Inc.